e8vk

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of earliest event reported: October 14, 2004

QLT INC.

(Exact Name of Registrant as Specified in Charter)


British Columbia, Canada	000-17082	N/A

(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

887 Great Northern Way, Vancouver, B.C. Canada, V5T 4T5

(Address of Principal Executive Offices) (Zip Code)

(604) 707-7000

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[ ]		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS


	ITEM 8.01 OTHER EVENTS.
	ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

ITEM 8.01 OTHER EVENTS.

On October 14, 2004, QLT Inc. announced that it will continue its Visudyne® in Occult (VIO) trial to the 24 month endpoint. A copy of the press release is attached as exhibit 99.1 hereto and incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits


			99.1			Press release dated October 14, 2004, announcing continuation of QLT’s Visudyne® in Occult (VIO) trial to the 24 month endpoint.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

QLT INC.
(Registrant)

By: /s/ Michael J. Doty
Michael J. Doty
Dated: October 14, 2004 Senior Vice President and Chief Financial Officer

EXHIBIT INDEX


Exhibit
No.		Description
99.1		Press release dated October 14, 2004, announcing continuation of QLT’s Visudyne® in Occult (VIO) trial to the 24 month endpoint.

Table of Contents

Table of Contents

Table of Contents

Table of Contents


	QLT INC. (Registrant)
	By:	/s/ Michael J. Doty
		Michael J. Doty
Dated: October 14, 2004		Senior Vice President and Chief Financial Officer